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Abstract: Background&Aims. Sorafenib is associated with multiple adverse events (AEs),
potentially causing its permanent interruption. The impact of the physicians experience
on the management of these AEs and the relative implications on clinical outcomes are
unknown. We verified if the AEs management changed over time and if these
modifications impacted on treatment duration and overall survival (OS).
Methods. We analysed the prospectively collected data of 338 consecutive patients
who started sorafenib between January 2008 and December 2017 in three tertiary care
centres in Italy. Patients were divided according to the starting date: Group A (2008-
2012; n=154), and Group B (2013-2017, n=184). Baseline and follow up data were
compared. In the OS analysis, patients who received second-line treatments were
censored when starting the new therapy.
Results. Baseline characteristics, AEs, and radiological response were consistent
across groups. Patients in Group B received a lower median daily dose (425 vs 568
mg/day, p<0.001) due to more frequent dose modifications. However, treatment
duration was longer (5.8 vs 4.1 months, p=0.021)  with a trend toward a higher
cumulative dose in Group B. Notably, the OS was also higher (12.0 vs 11.0 months,
p=0.003) with a sharp increase in the 2-year survival rate (28.1 vs 18.4%, p=0.003) in
Group B. The multivariate time-dependent Cox regression confirmed later period of
treatment as an independent predictor of survival (HR 0.728, 95%CI 0.581-0.937,
p=0.013). Unconsidered confounders were unlikely to affect these results at the
sensitivity analysis.
Conclusions: experience in the management of sorafenib-related AEs prolongs
treatment duration and survival. This factor should be considered in the design of
future randomised clinical trials including a sorafenib treatment arm, as an
underestimate of sample size may derive.
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July 10, 2019 
To the Editor of Journal of Hepatology 
Dear Professor, 
Please find enclosed the revised version of our manuscript titled “IMPROVED MANAGEMENT OF ADVERSE 
EVENTS WITH TAILORED SORAFENIB DOSING PROLONGS SURVIVAL OF HEPATOCELLULAR CARCINOMA 
PATIENTS” to be submitted as an Original Article for consideration of publication. 
First of all, we would like to thank both the Editor and the Reviewers for their interest in the original 
version of our paper and for their precious suggestions. We included a detailed point-to-point response to 
all of the considerations raised by the Editor and Reviewers. We feel that these suggestions helped us into 
improving the quality of our paper. However, we are open to any further option which could be helpful in 
clarifying any remaining doubt and in further improving our manuscript. 
 
On behalf of the Authors 
Francesco Tovoli, MD   
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Editors' comments: Your manuscript has been evaluated by two experts in the field and by the board of editors. Although the 
reviewers agree that the manuscript is interesting and has potential future therapeutic implications, they raised substantive concerns. Moreover, 
the authors have to mention a very similar paper has been published recently (DOI: 10.1159/000497161). Under these circumstances the journal is 
unable to accept your manuscript in its present form, but the journal will accept to review a revised version of your manuscript if you feel you can 
deal with all the reviewers' comments. 
We would like to thank the Editor for the interest in our paper. The paper DOI: 10.1159/000497161 is indeed similar to our work. The main 
differences are represented by the multicenter design, the larger dimension of the two cohorts (which allowed more elaborate analyses of the 
prognosticators), the censoring of patients at the beginning of the second line treatment, and the confirmation of the actual effect of the period 
of treatment in a multivariate analysis. The latter point was lacking in the previous paper and, in our opinion, represent an important element of 
novelty. The paper by Raoul et al had been previously mentioned only in the Discussion. We further quoted this paper in the Introduction. This 
paper is now being referenced in the following sentences 
INTRODUCTION: “A very recent monocentric study [10] suggested that the experience in managing sorafenib AEs has improved overtime, but 
rigorous multicentric studies taking into account also time-dependent variables, addressing the possible confounding factor of second-line 
treatments, and providing a confirmation of the survival benefit through multivariable regressions models are still lacking” 
DISCUSSION: “Only very recently, Raoul and colleagues [10] reported similar results in a retrospective monocenter study. Their report of an increase 
in treatment duration from 4.3 months in 2008-2012 vs 5.9 months in 2013-2017 is strikingly similar to our results. Our study provides a validation 
of these initial results through a large multicenter collaboration. DISCUSSION:” In the aforementioned study by Raoul et al. [10], the OS was in fact 
significantly higher in the last five years (12 vs 8 months) in the univariate analysis, but it was not possible to confirm this result also in a 
multivariate regression.” 
Further notes to the Editor 
1. We updated the COI of the Authors as of 10 Jul 2019 
2. We added a lay summary as per Revised Manuscript Checklist point 1b.. 
3. We added a specification about the identity of Ethic Commettees approving the study as per Revised Manuscript Checklist point 3a. 
4. We added a statement about the statistical software used for statistical analyses as per CTAT table point 1.7 
5. Discussion: we added reference 29 to provide a very updated guide to the rapidly evolving scenario of first line trials using sorafenib as a 
comparator drug. 
 
 
Reviewer #1: This study represents a retrospective analysis of prospectively collected data on patients receiving sorafenib for advanced 
hepatocellular carcinoma. The topic is clinically relevant, carefully conducted and the results are interesting, despite the inherent risk of bias due 
to the retrospective design of the study and possible time/era related factors. The message in the discusion is clear and the conclusions are of 
interest to the field. 
We thank the reviewer for appreciating our paper. 
 
 
Reviewer #2: I read with great interest the paper entitled "Improved management of adverse events with tailored sorafenib dosing 
prolongs survival of hepatocellular carcinoma patients". In this manuscript, the authors try to expose the impact of the acquired experience with 
sorafenib in the outcomes of patients with hepatocellular carcinoma treated with this drug. For this aim, they designed a multicenter retrospective 
study where three centers were invited to participate. These authors show that the better understanding of safety profile and its management 
allow a longer exposure to the drug, what leads to a longer survival. 
Despite the interest of the work, it lacks novelty, as the authors expose in the manuscript in regards of the work by Raoul et al. Nevertheless, the 
description of events and statistical approaches that were done for this manuscript are very valuable. 
Detailed Response to Reviewers
Comments: 
 
METHODS 
1)       Why did you consider mRECIST criteria instead of RECIST criteria? Modified RECIST is not validated for the response assessment as may 
overestimate objective response. 
We agree that RECIST 1.1 are more broadly accepted than mRECIST in the evaluation of the response to systemic treatments. Therefore, we 
modified our manuscript adopting RECIST instead of mRECIST.   After this re-categorization, only 2 of the 4 complete responses and less than a 
half of the partial responses were confirmed. Instead, both criteria equally identified progressors, so the rate of PD was identical.  The difference in 
terms of response between the study groups remained nonsignificant (p=0.688).  
We modified the Methods – Biochemistry and imaging evaluation section as follows: “Radiologic evaluation of response during follow-up was done 
by CT-scan according to the Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 [15]. These criteria were preferred over the modified RECIST 
(mRECIST) [16,17] due to the possible overestimation of tumor necrosis in the setting of systemic treatments by the latter criteria  [18].” We also 
updated Figure 1 with the new results. 
 
2)     In terms of sorafenib discontinuation, radiological progression was enough for discontinuing the drug in those patients elegible for second-
line drugs. In the first period of the study there were no approved drugs, and second-line trials were scarce. Did you evaluate this in your 
analyses? This may impact in the evaluation of outcomes (For instance, those patients in the first period could have been treated for longer 
periods as sorafenib could not have been discontinued because of the lack of second line options). 
We were aware of this possible bias when the study was designed. Nonetheless, To reduce the risk of bias we decided to censor the patients at 
the start of the second-line treatment. This choice was necessary to avoid he confounding factor of second line therapies on survival, but led to a 
greater risk of losing follow-up information in the second period of the study. Therefore we evaluated the C-index to verify the entity of this loss. 
This test confirmed a better completeness in the first period due to the paucity of second-line trials in that timeframe, however, the loss of 
completeness in the second group was negligible in absolute and clinical terms, even if there are no tests to perform an analytical comparison of 
the two C-index values (please also see response to Point 5).  Indeed, even if the risk of a significant bias was ruled out, we agree with the 
comment by the reviewer about the possibility of a more prolonged sorafenib treatment in the first period (when less trials were available). This 
bias, however, would have been significant only in the instance of an actually longer period of treatment and OS in the first group.  As such, the 
impact of our findings is not lessened but rather strengthened by this factor. We thank the reviewer for this useful insight and we added the 
following lines to the Discussion session:  
“This longer treatment duration in the second period is even more striking if we take into the account the possible interference derived by the 
absence of approved drugs and the relative paucity of clinical trials in the first period of the study. This different clinical setting, in fact, could have 
lead to longer treatment durations in the first period, as sorafenib could not have been discontinued to offer second line options, as they were 
lacking at that time”. 
 
3)       Why did you consider 12 and 24 months as cut-offs for landmark analyses? What is the rational for it in the setting of advanced HCC? 
We agree that more information about this choice are needed. The 12 months cut-off was chosen to reflect the most recently described median 
overall survival of sorafenib-treated patients (REFLECT trial). The reasons for the 24 months cut off was twofold: first, it describes the exact double 
value of the median survival; second, it was recently adopted as a cut-off to define long-survivors. The same cut-off were used in the landmark 
analyses of an ancillary study of the REFLECT trial (Kudo et al, ABS 186, ASCO GI 2019 San Francisco) 
We added the following lines to the Methods section: The choice of these cut-offs derived from the most recently described median OS of sorafenib-
treated patients in the REFLECT trial [9] and by the recently proposed cut off to define long survivors to sorafenib [7,21], respectively. The same cut-off 
were used in the landmark analyses of a recent ancillary study of the REFLECT trial [22]. 
 
 
RESULTS 
4)       Study population: You have not explained the rational for choosing the two periods. Therefore, what is the rational for 2008-2012 and 
2013-2017, instead of other periods? 
 We are sorry for having omitted this critical information. We added the following lines in the Design of the study section: “For the purpose of this 
study, the whole 2008-2017 timeframe was divided in two exactly equally long periods (January 2008 – December 2012 and January 2013 – 
December 2017). 
 
5) Baseline characteristics: Did you evaluate the possibility of DAA treatment for HCV-related HCC? This may impact in the differences of the 
treatment duration between the two periods, as patients achieving SVR are at lower risk of liver decompensation, and therefore, may be treated 
for longer periods of time. Moreover, if you have patients treated with DAA, it would be interesting to know if they have a more aggressive tumor 
behavior or not. 
We considered the possibility of a greater number of HCV patients being in SVR in the second period due to a larger availability of DAA.  
However, this possibility was not confirmed when we compared the rate of SVR in HCV patients in the two periods (12.4 and 14.1% in the first and 
second period, respectively).  The risk of liver decompensation due to an active HCV replication was consequently similar in the two groups.  
These results are probably due to the regulatory policies of the Italian Drug Agency, which do not allow the prescription of DAA in patients with 
active HCC, regardless of its stage (as a consequence, viraemic patients with early- or intermediate-stage HCV-related HCC who transitioned to 
the advanced stage never received DAAs). On the contrary, patients could have received DAA only if they never had HCC or if they had a 
complete response to previous treatments. Both of these hypothesis accounted only for a minority of our patients. However, we agree with the 
reviewer about the opportunity of adding additional information about HCV-positive patients. Therefore we modified the part of the “Baseline 
characteristics” describing viral infections as follows:  
“Amongst patients with HCV-related liver disease, the rate of HCV-RNA positive patients was 87.6 and 85.9% in Groups A and B, respectively 
(p=0.748). These proportions accounted for 19 and 26 patients in sustained virological response in the first and second period, respectively. All of the 
19 patients in the 2008-2012 period had achieved a sustained virological response after interferon-based treatments. Amongst the 26 patients who 
started sorafenib in the 2013-2017 period, 18 had eradicated the HCV infection with interferon-based treatments and 8 with second-generation 
direct antiviral agents.”  
We also would like to thank the reviewer for suggesting to verify whether post-DAA HCC had a more aggressive tumor behavior. We added the 
following lines: 
METHODS: “Patients with HCV-related cirrhosis in sustained virological response after a viral eradication with direct anti-viral agents were 
considered a group of special interest, as recent reports suggested that they might develop a more aggressive form of HCC”  
RESULTS: “With the limitations of the reduced sample size (n=8), patients with post-DAA HCC had a more frequent onset directly in the advanced 
stage (75.0%), but their response to sorafenib was not worse compared to the remaining study population (disease control rate 62.5%). Also, the OS 
of these patients was not significantly impaired (median 12.0 months).” 
DISCUSSION: “The eight patients previously treated with direct antiviral agents had a more frequent onset in the advanced stage as previously 
described by Reig at al, but their response to sorafenib was not different from that of the remaining study population.” 
 
6) Follow up: It looks like the C-index is different among the two groups. Did you evaluate if differences were statistically significant? And if so, 
what is your explanation for it? 
To the best of our knowledge, the C-index as designed by Clark et al is meant to provide a descriptive analysis of the completeness of the follow-
up but does not allow an analytical comparison between groups. That said, we agree that there is a slight difference between the two groups that 
is justified by a greater number of patients being censored due to the availability of post-sorafenib treatments. We reported these considerations 
into the paper: 
DISCUSSION: “Censoring the survival of patients who received second-line treatments excluded the longer OS was justified by improvements in 
oncological treatments. This choice caused a slightly lower completeness of the follow up in the second group, which, however, remained very high in 
absolute terms”. 
 
7) Adverse events evaluation and management: Did you check if there were differences in terms of patients' comorbidities? This may be an 
important issue, as we are probably more conservative treating some patients with some clinical conditions (heart diseases, etc.) that what we 
were before. This may also impact in the length of treatment in the periods analyzed.  
Comorbidies are indeed a significant problem in the prescription and management of sorafenib, especially cardiovascular diseases. We actually 
found a relatively low proportion of patients with cardiovascular comorbidities, with no significant differences across the periods of treatment. 
This finding is probably justified by our basically strict adherence to the indications and contraindications of sorafenib since its licensing in 2008, 
especially in terms of  cardiovascular comorbidities. In detail, sorafenib was prescribed only in very selected cases of patients with symptomatic 
congestive heart failure or coronary hearth disease, based on the earlier evidence of potentially severe adverse events of sorafenib and other TKIs 
in these cases (PMID: 18838713)(PMID: 19734999). We reported the following information: 
METHODS – Baseline evaluation: “We recorded the following data for each patient at the time of the first prescription of sorafenib: time elapsed since 
the first diagnosis of HCC, previous treatments for HCC, aetiology of the underlying liver disease, presence/absence of liver cirrhosis, and 
comorbidities.” 
RESULTS – Baseline characteristics: “Finally, we found a similar rate of comorbities in the two groups (ACCESSORY TABLE 1)”. 
DISCUSSION – “First, the baseline characteristics of the patients were similar in the two groups in terms of tumour burden, liver function, 
performance status, comorbidities, and number of previous TACE procedures, making the hypothesis of an improved referral of the patients unlikely 
as a possible alternative explanation”. 
 
8)       From 2008 to 2017, the classification of adverse events has changed (CTCAE 3.0, CTCAE 4.03). Did you check if the classification of severity 
was comparable among the two groups? For instance, definition of grade 2/3 of rash, dry skin, hypertension, etc. has changed between these two 
versions. This concern is applicable also to table 2. 
The reviewer raises an important point. The classification of severity of adverse events had been made comparable for the two groups In the 
original version of the paper as we were aware of this potential bias. This operation was possible as clinical records included not only the grade of 
each adverse event but also a brief description. For instance, we were able to re-codify hypertension as blood pressure values and prescribed 
anti-hypertensive drugs were recorded in the clinical data, instead of a mere report of “hypertension G2”. Similarly, in case of skin rash, we 
recorded the percentage of the body surface area, the characteristics of the rash, the presence of symptoms (such as pruritus), etc.  We added the 
following information: 
METHODS - Adverse events evaluation and management: “The medical records included both  a brief description of each AE as well as its coding 
according to the Common Terminology Criteria for Adverse Events (CTCAE) used at the time of registration. Since the CTCAE version was upgraded 
from version 3.0 to version 4.03 in June 2010, all of the AEs occurred before that date were re-codified according to the newer version to allow a 
correct comparison between groups.” 
 
9)       Imaging evaluation: You describe that almost a 10% of patients in both groups died before the first imaging evaluation. This percentage is 
comparable to the hyperprogression rate in patients treated with check-point inhibitors. Did these patients exhibit any kind of specific profile? 
Did they have any kind of adverse event, such as (for instance) diarrhea? Please, add a comment in this regard. 
We thank the reviewer for the interesting parallel with the hyperprogression. We analysed the characteristics of the patients who died before the 
first imaging evaluation. A sizeable proportion of this  population had a Child-Pugh B class at baseline (24.1%). Other traditionally negative 
predictors of survival were also relatively prevalent in this population, such as PS=1 (48.3%) and AFP>400 ng/ml (41.4%). Instead, the rate of AEs 
was lower in comparison with the remaining population (dermatological AEs 13.8%, diarrhea 13.8%, hypertension 17.2%). This pattern could be 
explained by the fact that these patients simply did not live enough to develop AEs. Also, in the case of dermatological AEs, the lack of these 
manifestations can be seen as a further negative prognostic factor. We added these considerations in the appropriate section, 
 
10)      Permanent sorafenib discontinuation: Did you evaluate the type of progression in patients who progressed? If so, is this pattern similar 
between the two groups? Different patterns of progression may explain different outcomes in the groups. 
We thank the reviewer for suggesting to analyse another potential confounding factor. We were able to assess the progression pattern as 
described by Reig et al in the 198 patients who had a documented radiological progression (227 total progressors minus 29 patients who died 
before performing a follow up imaging). The rates of BCLCp-B, BCLCp-C1 and BCLp-C2 were comparable across the two groups. We added he 
following information: 
METHODS – Permanent discontinuation of sorafenib: “In patients who discontinued sorafenib for progression, the impact of the pattern of  
progression [REIG]  on the post-progression survival was also analysed. Post progression survival was defined as the time from the last dose of 
sorafenib and death.” 
RESULTS – Permanent discontinuation of sorafenib: “For the 198 patients who had a documented radiological progression at the time of sorafenib 
discontinuation, the pattern of progression was similar (BCLCp-B 26.2 vs 26.3%; BCLCp-C1 39.3 vs 38.6%; BCLCp-C2 34.5 vs 35.1%) in Group A and 
B, respectively (p=0.994).” 
DISCUSSION – “Second, in a similar line, the duration of treatment and the median daily dose were the only significantly different variables in the 
follow-up of the two groups, thus excluding an imbalance in other confounding factors (for instance, a difference in the pattern of progression)” 
 
11)      Permanent sorafenib discontinuation: How did you define sorafenib intolerance? 
Sorafenib intolerance was defined as the presence of unmanageable grade 2‐4 AEs not responding to dose reductions and/or temporary 
interruption of treatment. This definition was also used in the referenced paper by Iavarone and colleagues (Hepatology 2015). We added this 
information under the METHODS – Permanent discontinuation of sorafenib session.  
 
12)       OS evaluation and correlates: How do you explain that extrahepatic spread was not found to be a predictor of survival? 
The lack of a statistically significant correlation between extrahepatic spread and overall survival has  been further investigated. At the univariate 
analysis, the median OS was 13.5 and 9.9 months for non-metastatic and metastatic patients respectively. The survival curves of patients with and 
without extrahepatic spread, however, crossed at about 30 months due to a relatively slower slope of the curve of metastatic patients. In its turn, 
this finding reflected the presence of a subgroup of patients with limited extrahepatic spread who achieved a long-lasting radiological disease 
control (about 18% of all metastatic patients). We added the following considerations to the Results session: 
“Extrahepatic spread did not reach the full statistical significance as a predictor of OS in our series (p=0.111). The lack of a significant result was due 
to the presence of a subgroup of patients with limited extrahepatic spread (18% of all metastatic patients) who achieved a long-lasting radiological 
disease control.” 
 
13)       OS evaluation and correlates: Did you try to introduce the pattern of progression in regression analyses? It could be also useful for a 
better understanding of the results. 
We thank the reviewer for this useful suggestion. We performed an additional survival analysis to assess the relationship between the pattern of 
progression and the post-progression survival. This analysis included the 198 patients who had a documented radiological progression (227 total 
progressors minus 29 patients who died before performing a follow up imaging). We found significantly different post progression survival for the 
BCLCp-B, BCLCp-C1 and BCLCp-C2 patterns, thus validating the prognostic ability of the BCLC upon progression classification.  We added the 
following lines: 
RESULTS: The pattern of progression was significantly correlated with the post-progression survival. The median OS was 11.0 [95% CI 7.4-14.8], 6.0 
[95% CI 4.2-7.6], and 4.7 [95% CI 3.4-6.2] months in the BCLCp-B, BCLCp-C1 and BCLCp-C2 classes, respectively (p<0.001). Progression due to new 
extrahepatic lesion(s) was associated with a significantly worse post-progression survival compared to other patterns of progression (4.9 [95% CI 3.1-
6.5] vs 8.0 [95% CI 5.6-10.0]months , p<0.001). 
 
14)      OS evaluation and correlates: Did you consider including the number of previous TACE procedures (obviously in those patients treated 
with TACE) in the regression analyses? We have great evidence supporting a "quick" migration to systemic treatment if TACE fails, and we are 
probably doing so nowadays. However, it is highly likely that patients in the group A received more TACE sessions than those in group B. These 
first patients could have been at higher risk of liver decompensation, leading to a shorter period of time under systemic treatment and have 
shorter OS. Please, add a comment in this regard. 
We are grateful to the reviewer for pointing out this possible confounder. We fully agree that an early migration is a key element to rescue the risk of 
liver function decompensation and  let the patients have the greatest likelihood of receiving the maximum survival benefit from the systemic 
treatments.  Actually, the participating centers had been always skeptical about the benefit of countless TACE treatments even in the immediate pre-
sorafenib era, due to previous experience of the low likelihood of tumor control and the parallel increase in the risk of deocmpensation. As a 
consequence, no significant differences in the number of previous TACE procedures were found in the two groups. In particular, the rate of patients 
who had received more than 2 TACE was relatively low (20-25% in both groups). These findings reflected into the rate of patients who discontinued 
sorafenib due to liver decompensation, who was also very similar in the two groups. The description of the number of TACE was now added to Table 
1. 
Moreover, as suggested by the reviewer, we performed a subgroup analysis including the patients who had received at least one TACE. Two 
multivariate regressions were created, using different cut-offs to identify a possible detrimental role of repeated TACE. The results of these analyses 
supported the importance of a quick migration to systemic treatments and have been added in the following paragraph: 
“Results – Subgroup analyses - Patients previously treated with trans-arterial chemoembolization (TACE): Overall, 58.4 and 55.4% of patients of the 
Group A and Group B had received at least TACE before the first dose of sorafenib. As reported in Table 1, there was no difference in the number of 
TACE (p=0.270). To investigate a possible detrimental effect of repeated TACE, we created two different multivariate regressions which included only 
the subgroup of patients which received at least one TACE.  
In the first model, we set 2 TACE as a cut-off (1-2 vs 3 or more TACE). In this case, the number of previous TACE met a borderline significance at the 
univariate analysis (p=0.083) and was not confirmed as an independent predictor of survival at the multivariate Cox regression (p=0272). 
In the second model, the cut-off was set at 3 TACE (1-3 vs 4 or more TACE). In this model, the number of previous procedures still met a borderline 
significance at the univariate analysis (p=0.056), but this time was confirmed as a prognosticator at the multivariate regression (HR 1.595, 95% CI 
1.065-2.390, p=0.024). 
Notably, the period of treatment was confirmed as an independent predictor of survival both in the first (HR 0.703, 95% CI 0.513-0.963, p=0.028) and 
in the second model (HR 0.693, 95% CI 0.506-0.949, p=0.022) despite the reduced statistical power of the subgroup analyses.” 
 
 
TABLE 1 
15)     In the legend, you mention that you are describing median and IQR. However, it looks like the values that you are describing are standard 
deviations. I recommend checking it. 
 
The interquartile range is now correctly reported in the Table. 
 
FIGURE 1 
-       The use of mRECIST overestimates complete response (and objective response). In my opinion, it would be a good idea reporting objective 
response using RECIST rather than mRECIST. 
The Figure now reports the partial response and complete response rates according to RECIST 1.1 
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ABSTRACT 
 
Background&Aims. Sorafenib is associated with multiple adverse events (AEs), potentially causing its 
permanent interruption. The impact of the physicians experience on the management of these AEs and the 
relative implications on clinical outcomes are unknown. We verified if the AEs management changed over 
time and if these modifications impacted on treatment duration and overall survival (OS). 
Methods. We analysed the prospectively collected data of 338 consecutive patients who started sorafenib 
between January 2008 and December 2017 in three tertiary care centres in Italy. Patients were divided 
according to the starting date: Group A (2008-2012; n=154), and Group B (2013-2017, n=184). Baseline and 
follow up data were compared. In the OS analysis, patients who received second-line treatments were 
censored when starting the new therapy. 
Results. Baseline characteristics, AEs, and radiological response were consistent across groups. Patients in 
Group B received a lower median daily dose (425 vs 568 mg/day, p<0.001) due to more frequent dose 
modifications. However, treatment duration was longer (5.8 vs 4.1 months, p=0.021)  with a trend toward a 
higher cumulative dose in Group B. Notably, the OS was also higher (12.0 vs 11.0 months, p=0.003) with a 
sharp increase in the 2-year survival rate (28.1 vs 18.4%, p=0.003) in Group B. The multivariate time-
dependent Cox regression confirmed later period of treatment as an independent predictor of survival (HR 
0.728, 95%CI 0.581-0.937, p=0.013). Unconsidered confounders were unlikely to affect these results at the 
sensitivity analysis.  
Conclusions: experience in the management of sorafenib-related AEs prolongs treatment duration and 
survival. This factor should be considered in the design of future randomised clinical trials including a 
sorafenib treatment arm, as an underestimate of sample size may derive. 
 
Lay summary. Sorafenib is the standard frontline systemic treatment for hepatocellular carcinoma since 
over a decade. Its tolerability is limited by different adverse events which might lead to its permanent 
discontinuation in sizeable proportion of patients. After a careful analysis of potential confounders, we 
demonstrated that the physicians’ experience in managing adverse events related to sorafenib has 
improved overtime, with longer treatment periods and less permanent discontinuation for toxicities. More 
importantly, these improvements also translated into a longer survival of the patients. Our results have 
relevant repercussions in clinical practice and in the design of future clinical trials.   
 
Abstract word count: 275
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INTRODUCTION 
Sorafenib is a multitarget tyrosine kinase inhibitor (TKI) currently used for the treatment of hepatocellular 
carcinoma (HCC) not amenable to surgery or locoregional treatments [1]. Sorafenib significantly prolongs 
patients’ overall survival (OS), but its use is associated with different adverse events (AEs), mainly 
dermatological, gastrointestinal and cardiovascular [2,3]. The management of these AEs can require dose 
reductions and temporary interruptions. In a sizeable proportion of patients, however, these modifications 
are not able to avoid intolerable or severe AEs, resulting in permanent drug discontinuation [1]. It might 
seem common sense that the experience accumulated in the prescription of sorafenib could lead to 
improved management of its related AEs. However, the exact impact of the operators' experience on the 
prescribing patterns of sorafenib has been investigated rarely [4]. Similarly, it is not known whether this 
phenomenon can lead to an increase in OS. The latter point is of crucial importance, as dermatological AEs 
have been demonstrated to have a favourable prognostic impact [5,6]. Thus, avoiding a definitive 
suspension of sorafenib in these patients would be extremely beneficial. Moreover, data from 
observational studies [7,8] and randomised clinical trials (RCTs) [9] indirectly seem to suggest that the OS of 
patients treated with sorafenib is progressively increasing. However, the reasons for this phenomenon have 
not been fully elucidated. A very recent monocentric study [10] suggested that the experience in managing 
sorafenib AEs has improved overtime, but rigorous multicentric studies taking into account also time-
dependent variables, addressing the possible confounding factor of second-line treatments, and providing a 
confirmation of the survival benefit through multivariable regressions models are still lacking.  
The primary objective of our study is to verify whether the treatment schedules of sorafenib (in terms of 
average daily dose, duration of treatment, cumulative dose) and the percentage of discontinued patients 
for intolerable AE varied over time. The secondary objective was to verify if these differences had a 
correlation with the OS after corrections for confounders. 
METHODS 
Design of the study 
The present study was performed using the medical records from the databases of Sant’Orsola-Malpighi 
Hospital, University of Bologna, Italy; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) 
IRCCS, Meldola, Italy; and Degli Infermi Faenza Hospital, Italy. All of these databases include prospectively 
collected consecutive patients prescribed with sorafenib and followed up. Data were entered every 3-6 
months into electronic data files by co-investigators from each centre taking part and checked at the data 
management centre for internal consistency. For the purposes of this study, we retrospectively considered 
patients who were prescribed from January 2008 to December 2017. The starting date coincides with the 
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 4 
licensing of sorafenib in Italy, and therefore with the possibility of prescription by all of the study centres. 
The closing date preceded the licensing of regorafenib in Italy by one year and was chosen to allow an 
adequate follow-up of the patients. For the purpose of this study, the whole 2008-2017 timeframe was 
divided in two exactly equally long periods (January 2008 – December 2012 and January 2013 – December 
2017). The closing time for last follow up was 31 March 2019. 
Baseline evaluation 
We recorded the following data for each patient at the time of the first prescription of sorafenib: time 
elapsed since the first diagnosis of HCC, previous treatments for HCC, aetiology of the underlying liver 
disease, presence/absence of liver cirrhosis, and comorbidities. The main parameters entailing the residual 
liver function according to the Child-Pugh score were also registered. Finally, we included data about the 
tumour staging according to the Barcelona Clinic for Liver Cancer (BCLC) classification. The baseline values 
of alfa-fetoprotein (AFP) were also available for all patients. Patients with HCV-related cirrhosis in sustained 
virological response after a viral eradication with direct anti-viral agents were considered a group of special 
interest, as recent reports suggested that they might develop a more aggressive form of HCC [11]. 
Sorafenib prescription 
All patients were prescribed with sorafenib at the initial dose of 400 mg twice a day.  At the time of the first 
prescription of sorafenib, all patients were provided with a diary and instructed about the possible 
sorafenib-related AEs to allow early recognition and treatment. A preventive application of urea cream 20% 
on hands and feet twice a day, plus loperamide as an over-the-counter medication in case of diarrhoea 
were recommended. Patients were advised to measure blood pressure every day and to contact their 
respective centres in case of new symptoms. 
Adverse events evaluation and management 
New symptoms arising after the treatment start, as well as their timing, were thoroughly recorded. The 
medical records included both  a brief description of each AE as well as its coding according to the Common 
Terminology Criteria for Adverse Events (CTCAE) used at the time of registration. Since the CTCAE version 
was upgraded from version 3.0 to version 4.03 in June 2010, all of the AEs occurred before that date were 
re-codified according to the newer version to allow a correct comparison between groups. Dose 
modifications in response to the AEs (including dose reductions and dose stops) were performed according 
to the manufacturer's recommendations. When sorafenib became available in 2008, the dose modifications 
were performed in strict accordance with the instruction contained in the SHARP protocol [2]. As a result, 
dose stops were extremely limited, and dose reductions below the minimum recommended dose of 400 
mg once daily were rare, to aggressively reach the maximum tolerated dose in every single patient at every 
single moment. Patients who had recurring unmanageable toxicities at the dose of 400 mg once daily were 
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 5 
almost invariably discontinued for intolerance.  As the experience increased, this approach became less 
rigid and more patient-tailored. The main aim shifted to identify for each patient a regimen with limited 
toxicities but a higher likelihood of being tolerated on a longer term. For instance, in selected cases, very 
short dose stops (1-2 days) were performed even for Grade 2 toxicities, provided that: a) the patient 
perceived them as extremely limiting their quality of life; b) the physician regarded these toxicities as a 
potential threat to the compliance of the patient. Also, if AEs reappeared even after a 7-day dose stop and 
a subsequent dose reduction to 400 mg once daily, we became more prone at performing a further dose 
reduction to 200 mg once daily rather than permanently discontinue sorafenib. This new focus was 
supported by cumulative evidence favouring a tailored approach [12,13] and discouraging an aggressive 
treatment re-escalation [14]. 
Biochemistry and imaging evaluations 
As a general rule, under normal conditions, biochemistry was reassessed every 2 weeks during the first 8 
weeks of treatment, then every 4 weeks. The first imaging evaluation of response was scheduled 8-10 
weeks after the first dose of sorafenib, with the subsequent radiological controls scheduled every 12 
weeks. Computed tomography of thorax-abdomen-pelvis with iodinated contrast medium was the 
preferred imaging technique. For patients with contraindications to the iodinated contrast medium, a 
magnetic resonance imaging of the abdomen paired with a high-resolution computed chest tomography 
was performed. Radiologic evaluation of response during follow-up was done by CT-scan according to the 
Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 [15]. These criteria were preferred over the 
modified RECIST (mRECIST) [16,17] due to the possible overestimation of tumor necrosis in the setting of 
systemic treatments by the latter criteria  [18].  
Permanent discontinuation of sorafenib 
Sorafenib was continued until 1) radiological and clinical progression (for patients eligible for second-line 
clinical trials, radiological progression alone was considered a sufficient reason for discontinuation); 2) 
unacceptable AEs, or; 3)  deterioration of liver function. Categorisation into these classes was performed 
according to the same criteria previously proposed by Iavarone and colleagues [19].  In particular, sorafenib 
intolerance was defined as the presence of unmanageable grade 2‐4 AEs not responding to dose reductions 
and/or temporary interruption of treatment [19]. In patients who discontinued sorafenib for progression, 
the impact of the pattern of  progression [20] on the post-progression survival was also analysed. Post 
progression survival was defined as the time from the last dose of sorafenib to death. 
OS evaluation and correlates 
OS was measured from the date of starting sorafenib until the date of death. Patients who received a 
second-line treatment in the setting of clinical trials were censored at the time of the first dose of the new 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
therapy). The rate of long-survivors, defined as patients with an OS ≥ 24 months [7,17], was considered a 
variable of particular interest. Twelve- and 24-month landmark analyses were performed to further 
evaluate the long-term modifications of OS. The choice of these cut-offs derived from the most recently 
described median OS of sorafenib-treated patients in the REFLECT trial [9] and by the recently proposed cut 
off to define long survivors to sorafenib [7,21], respectively. The same cut-off were used in the landmark 
analyses of a recent ancillary study of the REFLECT trial [22]. To address the possible bias deriving from 
more second-line RCTs being available in the latest years (resulting in a higher number of censored patients 
in one group), a completeness quantification of the follow up was performed. Also, a sensitivity analysis 
was performed to evaluate how strong an unmeasured confounder would have to be to disprove the 
possibly observed relationship between the period of treatment and OS.  
Ethics 
The study protocol was reviewed and approved by the local Ethics Committees (Bologna Authority Hospital 
Ethic Committee for Bologna centre and Romagna Ethic Committee for Meldola and Faenza centres, 
respectively). All patients gave their written informed consent according to the Ethics Committees’ 
recommendations. The study was conducted according to the ethical guidelines of the 1975 Declaration of 
Helsinki. 
Statistics 
Continuous variables are expressed as median and interquartile range. Categorical variables are expressed 
as frequencies. Group comparisons were performed with the Mann–Whitney test. Categorical variables 
were evaluated using two‐tailed Fisher's test. Survival curves were estimated using the product-limit 
method of Kaplan-Meier. The role of stratification factors was analysed with log-rank tests. To define the 
predictors of OS we used a time-dependent covariates survival approach including statistically significant 
clinical variables (p <0.05) from the univariate Cox analysis. The completeness quantification of the follow 
up was performed according to the C-index, as proposed by Clark et al. [23]. Briefly, C-index is the ratio of 
the total observed follow-up years divided by the total potential follow-up years. In the case of our study, 
the observed follow-up for each patient was the time from study entry to the death or censoring. The 
potential follow-up for each patient was the time from study entry to the closing date of the study or 
patient death, whichever came first. The sensitivity analysis was performed calculating the E-value and the 
limit of its 95% confidence interval (CI) closest to the null [24,25]. Statistical analyses were performed using 
SPSS version 23.0 (SPSS Inc., Chicago, IL, USA) (Supplementary CTAT Table). 
RESULTS 
Study population 
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 7 
This study included 338 patients. Most patients were cirrhotic (96.8%), viral hepatitis was the leading cause 
of their chronic liver disease (HBV infection: 21,8%, HCV infection 49.7%, nonviral causes 28.5%). One 
hundred fifty-four patients started sorafenib in the 2008-2012 period (Group A), while the remaining 184 
patients began treatment in the 2013-2017 period (Group B). 
Baseline characteristics 
There were no significant differences in the baseline characteristics between the two groups, especially in 
terms of demographics, liver function, and tumour staging (TABLE 1). Amongst patients with HCV-related 
cirrhosis, the rate of HCV-RNA positivity was 87.6% and 85.9% in Groups A and B, respectively (p=0.748). 
Amongst patients with HCV-related liver disease, the rate of HCV-RNA positive patients was 87.6 and 85.9% 
in Groups A and B, respectively (p=0.748). These proportions accounted for 19 and 26 patients in sustained 
virological response in the first and second period, respectively. All of the 19 patients in the 2008-2012 
period had achieved a sustained virological response after interferon-based treatments. Amongst the 26 
patients who started sorafenib in the 2013-2017 period, 18 had eradicated the HCV infection with 
interferon-based treatments and 8 with second-generation direct antiviral agents.  No patients with HBV-
related cirrhosis were HBV-DNA positive at the time of sorafenib prescription. Finally, we found a similar 
rate of comorbities in the two groups (SUPPLEMENTARY TABLE 1). 
Follow up  
The median follow-up was 10.5 months (range 0.2-78.9), with no significant differences between study 
groups (10.3 vs 10.5 months in Groups A and B, respectively). The C-index was 94.0 % in Group A and 85.1% 
in Group B. 
Adverse events evaluation and management 
In both groups, almost every patient reported at least one AE after sorafenib start (TABLE 2). Overall, the 
rate of patients reporting at least one dermatological AE (hand-foot skin reaction or skin rash) was similar 
in the two groups (34.4% vs 38.0% in groups A and B, respectively, p=0.498). The rate of patients 
complaining of gastrointestinal symptoms was also similar in the two groups (42.9% vs 50.5%, p=0.189). 
The prevalence of treatment-related arterial hypertension was 24.8% in Group A and 27.8% in Group B 
(p=0.538). 
In most patients, the management of AEs required at least one dose modification. The rate of patients who 
required a dose reduction to 400 mg/day was higher in Group B than in Group A (86.4 vs 75.3%, p=0.009). 
Re-escalation to a higher dose, however, was possible for a sizeable number of patients in both groups. 
(TABLE 3) More patients received a dose reduction to 200 mg/day in Group B compared to Group A (30.4 vs 
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 8 
13.6%, p<0.001). In this case, the majority of patients tolerated a dose escalation to 400 mg/day. This refers 
to the first dose adjustment and not to the number of dose adjustments during follow-up. 
A similar number of patients received at least one temporary dose stop (87.5 vs 81.2%, p=0.130). However, 
the rate of patients who received a temporary dose stop in at least two different occurrences was higher in 
Group B compared to Group A (54.3 vs 42.2%, p=0.029).  
Imaging evaluation 
Fourteen (9.1%) and 15 (8.2%) patients died before the first imaging follow up in Groups A and B, 
respectively, in a clinical setting of early progression (p=0.846). A sizeable proportion of this  population 
had a Child-Pugh B class at the baseline (24.1%). Other traditionally negative predictors of survival were 
also relatively prevalent in this population, such as PS=1 (48.3%) and AFP>400 ng/ml (41.4%). Instead, the 
rate of AEs was lower in comparison with the remaining population (dermatological AEs 13.8%, diarrhea 
13.8%, hypertension 17.2%). After the first imaging evaluation, the objective response and the disease 
control rates were comparable across the study groups (FIGURE 1). In particular, the disease control rate 
was 51.3% in Group A and 56.5% in Group B (p=0.688). 
Permanent sorafenib discontinuation 
During the follow-up, sorafenib was permanently discontinued in all but 4 patients, all of them belonging to 
the Group B. The median treatment duration was significantly higher in Group B (5.8 vs 4.1 months, 
p=0.021), with a lower median daily dose (425 vs 568 mg/day, p<0.001) compared to Group A.  There was a 
trend toward a higher cumulative dose in the Group B, which however did not reach the statistical 
significance  (75.0 vs 65.6 g, p=0.313). Progression was the main cause leading to permanent sorafenib 
discontinuation in both groups (TABLE 4). Of note, permanent discontinuation due to AEs was significantly 
higher in Group A compared to Group B (20.8% vs 9.2%, p<0.001). For the 198 patients who had a 
documented radiological progression at the time of sorafenib discontinuation, the pattern of progression 
was similar (BCLCp-B 26.2 vs 26.3%; BCLCp-C1 39.3 vs 38.6%; BCLCp-C2 34.5 vs 35.1%) in Group A and B, 
respectively (p=0.994).  
OS evaluation and correlates 
The multivariable analysis of factors related to the OS included all clinically statistically significant variables 
at the univariate analysis, considered for a forward stepwise approach. The multivariable analysis 
consistently identified Child-Pugh class, performance status, macrovascular invasion, alfa-fetoprotein ≥ 400 
ng/ml, the appearance of dermatological AEs and period of treatment (HR 0.728, 95%CI 0.581-0.937, 
p=0.013) as independent predictors of OS (TABLE 5). Extrahepatic spread did not reach the full statistical 
significance as a predictor of OS in our series (p=0.111). The lack of a significant result was due to the 
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 9 
presence of a subgroup of patients with limited extrahepatic spread (18% of all metastatic patients) who 
achieved a long-lasting radiological disease control.  
When dividing the patients according to their era of treatment, the median OS was significantly higher in 
Group B compared to Group A (12.0 vs 11.0 months, p=0.002) (FIGURE 2). Notably, the rate of long 
survivors was significantly higher in the Group B than in Group A, with a 2-year and 3-year survival rate of 
28.1 vs 18.4% (p=0.003) and 14.6 vs 6.8% (p=0.037), respectively. The landmark analysis largely confirmed 
these findings (FIGURE 3).  Analysing the patients according to their radiological response, the survival gain 
was particularly evident for patients who achieved disease control (21.5 vs 19.5 months, p=0.009). On the 
contrary, OS did not differ across the study groups for patients with progressive disease at their first 
imaging control (FIGURE 4).  
The sensitivity analysis reported an E-value of 1.356 for the association between period of treatment and 
OS. The limit of the 95% confidence interval closest to the null hypothesis was 1.335. These values mean 
that the observed association between OS and period of treatment could be nullified only by an 
unmeasured confounder associated with both OS and period, with a strength similar to that of 
performance status or AFP>400 ng/ml, which is very unlikely to have been missed. On the contrary, a 
weaker confounder could not disprove this association.  
Subgroup analyses 
- Patients previously treated with direct antiviral agents 
With the limitations of the reduced sample size (n=8), patients with post-DAA HCC had a more frequent 
onset directly in the advanced stage (75.0%), but their response to sorafenib was not worse compared to 
the remaining study population (disease control rate 62.5%). Also, the overall survival of these patients was 
not significantly impaired (median 12.0 months). 
- Patients previously treated with trans-arterial chemoembolisation (TACE) 
Overall, 58.4 and 55.4% of patients of the Group A and Group B had received at least TACE before the first 
dose of sorafenib. As reported in Table 1, there was no difference in the number of TACE (p=0.270). To 
investigate a possible detrimental effect of repeated TACE, we created two different multivariate 
regressions which included only the subgroup of patients which received at least one TACE.  
In the first model, we set 2 TACE as a cut-off (1-2 vs 3 or more TACE). In this case, the number of previous 
TACE met a borderline significance at the univariate analysis (p=0.083) and was not confirmed as an 
independent predictor of survival at the multivariate Cox regression (p=0272). 
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In the second model, the cut-off was set at 3 TACE (1-3 vs 4 or more TACE). In this model, the number of 
previous procedures still met a borderline significance at the univariate analysis (p=0.056), but this time 
was confirmed as a prognosticator at the multivariate regression (HR 1.595, 95% CI 1.065-2.390, p=0.024). 
Notably, the period of treatment was confirmed as an independent predictor of survival both in the first 
(HR 0.703, 95% CI 0.513-0.963, p=0.028) and in the second model (HR 0.693, 95% CI 0.506-0.949, p=0.022) 
despite the reduced statistical power of the subgroup analyses. 
- Pattern of progression and post-progression survival 
The pattern of progression was significantly correlated with the post-progression survival. The median OS 
was 11.0 [95% CI 7.4-14.8], 6.0 [95% CI 4.2-7.6], and 4.7 [95% CI 3.4-6.2] months in the BCLCp-B, BCLCp-C1 
and BCLCp-C2 classes, respectively (p<0.001). Progression due to new extrahepatic lesion(s) was associated 
with a significantly worse post-progression survival compared to other patterns of progression (4.9 [95% CI 
3.1-6.5] vs 8.0 [95% CI 5.6-10.0]months , p<0.001). 
 
DISCUSSION 
 
We provide direct evidence supporting two novel findings. First, the management of sorafenib-related AEs 
has changed over time, now allowing a longer duration of treatment. Second and most important, these 
changes also translate into a survival gain. 
Regarding the first point, our study provides the first direct confirmation of previous indirect evidence. In 
the registrative Phase 3 SHARP trial [2], 38% of patients had to discontinue sorafenib due to intolerable 
AEs. Subsequent observational studies which enrolled populations in the first four years following sorafenib 
licensing (and therefore comparable to Group A of our study) showed a comparable rate of discontinuation 
for toxicities. For example, in a large sorafenib field practice study including 296 patients recruited in 2008-
2010, this rate was about 40% [26]. In their prospective study on the role of dermatological AEs, Reig et al. 
[5] reported a withdrawal rate for AEs of 30.5% amongst 147 patients enrolled in the 2008-2011 period. 
This rate was slightly lower (21%) in the real-life GIDEON study (comprising 3371 patients enrolled in 2009-
2012) [8]. On the other hand, another large multicenter observational study (INSIGHT) evaluated patients 
enrolled up to 2014 and described a sensibly lower rate of patients with unmanageable intolerance (15.5%) 
[7]. This trend found further indirect confirmation from the second-line clinical trials of ramucirumab 
(REACH-2)  and pembrolizumab (KEYNOTE-224). The rate of patients entering these trials following 
sorafenib withdrawal for AES was 17.1 and 20.0%, respectively [27,28]. A final clue came from the 
noninferiority Phase 3 RCT lenvatinib vs sorafenib (REFLECT), in which only 7% of patients in the sorafenib 
treatment arm had to discontinue the drug due to AEs [9]. 
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In addition to the confirmation of this indirect evidence, our study also showed that a reduced interruption 
rate for AEs corresponds to an extension of the treatment duration. This longer treatment duration in the 
second period is even more striking if we take into the account the possible interference derived by the 
absence of approved drugs and the relative paucity of clinical trials in the first period of the study. This 
different clinical setting, in fact, could have lead to longer treatment durations in the first period, as 
sorafenib could not have been discontinued to offer second line options, as they were lacking at that time. 
This data was not inferable from previous observational studies, nor from the comparison of the SHARP and 
REFLECT data. While treatment beyond radiological progression was allowed in the first trial, progression 
automatically resulted in permanent treatment discontinuation as of protocol rules in the latter [2, 9]. Only 
very recently, Raoul and colleagues [10] reported similar results in a retrospective monocenter study. Their 
report of an increase in treatment duration from 4.3 months in 2008-2012 vs 5.9 months in 2013-2017 is 
strikingly similar to our results. Our study provides a validation of these initial results through a large 
multicenter collaboration. Of note, more flexible and personalised management of treatment scheduled 
also resulted in a lower median daily dose. This finding should not be seen as a justification to start 
treatment at a half dose or to be particularly indulgent with dose reductions and stops. Instead, it was the 
result of accumulating experience, which led to specific choices under well-defined circumstances, 
performed to balance the highest tolerable dose with the highest likelihood of achieving long term 
compliance. These choices were possible only thanks to a close follow up after sorafenib initiation, with 
easy access to unscheduled visits and consultations to detect AEs, manage them promptly, and adjust the 
dosage. Only in this scenario, it is possible to conjugate treatment compliance with optimal efficacy, 
without unneeded treatment interruptions or cancellations [5]. 
Most importantly, we demonstrated for the first time that experience in the management of AEs also has 
an impact on OS. While the median gain may seem modest (about one month), it should also be considered 
that the whole study population also included early progressors, i.e. patients for which improvement in the 
management of AEs is unlikely to mirror into a survival gain (as confirmed by our subgroup analysis). On the 
contrary, the median survival gain was doubled (about two months) in patients who achieved disease 
control. The difference in the rate of long survivors was even more striking. It can, therefore, be 
hypothesised that the improved management of AEs in responders patients reduced the risk of 
unnecessary drug discontinuation allowing a more extended treatment and a longer OS. So far there had 
been no direct demonstration of an improvement in the OS of patients treated with sorafenib over time. In 
the aforementioned study by Raoul et al. [10], the OS was in fact significantly higher in the last five years 
(12 vs 8 months) in the univariate analysis, but it was not possible to confirm this result also in a 
multivariate regression.  Even indirect evidence about the critical aspect of OS is minimal, deriving mainly 
from information collected in the REFLECT trial. In this study, the median OS in the sorafenib treatment arm 
was remarkably superior to that initially reported in the SHARP trial (12.4 vs 10.7 months). However, the 
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REFLECT study excluded patients with unfavourable prognostic factors (neoplastic occupation of the liver> 
50%, neoplastic thrombosis of the main portal trunk, biliary invasion) and this choice could at least partially 
justify the apparent improvement of the OS. As a consequence, no reliable information about OS 
modifications was available before our study.  
We are aware that analysing a possible period-effect can be tricky due to multiple possible analytical pitfalls 
and confounders. However, we have reasonable evidence to believe that our results were genuine. First, 
the baseline characteristics of the patients were similar in the two groups in terms of tumour burden, liver 
function, performance status, comorbidities, and number of previous TACE procedures, making the 
hypothesis of an improved referral of the patients unlikely as a possible alternative explanation. Second, in 
a similar line, the duration of treatment and the median daily dose were the only significantly different 
variables in the follow-up of the two groups, thus excluding an imbalance in other confounding factors (for 
instance, a difference in the pattern of progression). Third, censoring the survival of patients who received 
second-line treatments excluded the longer OS was justified by improvements in oncological treatments. 
While this choice caused a slightly lower completeness of the follow up in the second group,  the 
completeness remained very high in absolute terms. Fourth, innovations in non-oncological therapies are 
an equally unlikely alternative explanation, as demonstrated by both the unmodified OS in non-responder 
patients and the similar rate of HCV viraemic patients. In this regard, the 8 patients previously treated with 
direct antiviral agents had a more frequent onset in the advanced stage as previously described by Reig at 
al [11], but their response to sorafenib was not different from that of the remaining study population. 
Finally, any theoretical confounder not considered in the previous points should have required a very 
relevant impact on OS to disprove our results, as evidenced by sensitivity analysis. 
In conclusion, the increasing experience with the management of sorafenib-related AEs is leading to longer 
treatment duration and survival in responder patients. Our results have immediate implications, both in 
clinical and research terms. About clinical implications, a lower discontinuation rate for AEs implies better 
access to subsequent treatments. Regorafenib, for example, is only available for patients who progressed 
to sorafenib. At the same time, the improved management of AEs is extremely likely to translate also into 
optimised management of other TKIs (regorafenib, cabozantinib) with a cumulative OS advantage. As for 
research implications, the increasing median OS has obvious implications in the design of RCTs in which 
sorafenib is used as a comparator drug. In this case, an OS estimate based on the SHARP trial or early 
observational studies could lead to an underestimation of the sample size needed to reach a superiority or 
non-inferiority endpoint. The most immediate examples are the numerous trials of immune checkpoint 
inhibitors versus sorafenib in the frontline systemic setting [29]. These trials will be of critical importance in 
shaping the future therapeutic algorithms for the systemic treatment of HCC in the next future, and their 
results are eagerly awaited. Therefore, we suggest that the increased survival under sorafenib should be 
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considered in the design of future trials, to minimise the risk of unintentional failure due to an 
underestimated sample size. 
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TABLE 1. Baseline characteristics of study patients according the period of start of sorafenib. Continuous 
variables are expressed as median (interquartile range). Categorical variables are reported as frequencies 
(percentage) 
Variables 
2008 - 2012  
period (n=154) 
2013 - 2017 
period (n=184) 
P 
Age (years) 70 (62-75) 69 (58-75) 0.334 
Males 135 (87.7) 156 (84.3) 0.426 
Cirrhosis 149 (96.8) 178 (96.7) 1.000 
Etiology    
 - HBV 37 (24.0) 36 (19.6) 0.354 
 - HCV 75 (48.7) 93 (50.5) 0.745 
 - Nonviral 42 (27.3) 55 (29.9) 0.630 
Disease duration    
 - < 6 months 46 (31.2) 70(39.7) 
0.199  - 6-12 months 24 (14.9) 31 (15.8) 
 - > 12 months 84 (53.9) 83 (44.0) 
Bilirubin (mg/dl) 0.91 (0.62-1.26) 0.91 (0.64-1.20) 0.885 
Albumin (g/L) 36 (33-39) 36 (33-40) 0.566 
INR (ratio) 1.14 (1.06-1.25) 1.13 (1.06-1.23) 0.438 
Ascites 13 (8.4) 18 (9.8) 0.709 
Encephalopathy 6 (3.9) 4 (2.2) 0.522 
Child-Pugh B 11 (7.1) 16 (8.7) 0.690 
Tumor stage    
  - Intermediate (BCLC B) 54 (35.1) 72 (38.2) 
0.498 
 - Advanced (BCLC C) 100 (64.9) 112 (61.8) 
Performance status    
 - PS 0 98 (63.6) 130(70.7) 
0.200 
  -PS 1 56 (36.4) 54 (29.3) 
Macrovascular invasion 50 (32.5) 50 (27.2) 0.339 
Extrahepatic spread 51 (33.1) 76 (41.3) 0.143 
AFP >400 ng/ml 47 (30.5) 45 (24.5) 0.222 
Number of previous 
TACE procedures    
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 - None 64 (41.6) 82 (44.6) 
0.270 
 - One 24 (15.6) 32 (17.4) 
 - Two 28 (18.2) 32 (17.4) 
 - Three 20 (13.0) 18 (9.8) 
 - Four 11 (7.1) 16 (8.7) 
 - Five or more 7 (4.5) 4 (2.2) 
HBV: hepatitis B virus; HCV: hepatitis C virus; BCLC: Barcelona Clinic for Liver Cancer; AFP: alfa-fetoprotein; 
TACE: transarterial chemoembolisation. 
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TABLE 2. Prevalence of treatment-emergent adverse events (AEs) according to the period of start of 
sorafenib. Data are expressed as frequencies (percentage). 
Adverse Events (AEs) 
2008 - 2012 period 
(n=154) 
2013 - 2017 period 
(n=184) 
All grades Grade ≥ 3  All grades Grade ≥ 3  
Any AE 151 (98.0) 56 (34.4) 181 (98.1) 61 (33.2) 
Fatigue 96 (62.4) 18 (11.9) 133 (72.2) 12 (6.4) 
Diarrhea 61 (39.6) 9 (5.9) 86 (46.7) 7 (3.7) 
Hand foot skin reaction 45 (29.2) 6 (3.9) 63 (34.3) 14 (7.4) 
Hypertension 38 (24.8) 10 (6.5) 51 (27.8) 10 (5.5) 
Skin rash 15 (9.7) 3 (1.9) 19 (10.3) 7 (3.8) 
Weight loss 15 (9.7) 0 17 (9.2) 2 (0.9) 
Hyporexia 13 (8.4) 0 10 (5.4) 0 
Nausea 11 (7.1) 2 (1.3) 17 (9.2) 2 (0.9) 
Thrombocytopenia 9 (5.8) 2 (1.3) 13 (7.1) 0 
Alopecia 8 (5.2) NA 10 (5.4) NA 
Anaemia 7 (4.5) 2 (1.3) 5 (2.7) 0 
Leucopenia 6 (3.9) 2 (1.3) 8 (4.3) 2 (0.9) 
Dysphonia 6 (3.9) 0 7 (3.8) 2 (0.9) 
Mucositis 5 (3.2) 0 5 (2.7) 0 
Epistaxis 2 (1.3) 0 4 (2.2) 1 (0.5) 
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TABLE 3. Dose modification strategies in response to the treatment-emergent adverse events. Data are 
expressed as frequencies (percentage). 
  
2008 - 2012  
period (n=154) 
2013 - 2017 
period (n=184) 
P 
Dose reduction to 400 mg/day 113 (75.3) 157 (86.4) 0.009 
 - Re-escalation to 800 mg/day 34/113 (30.2) 35/157 (22.0) 0.341 
Dose reduction to 200 mg/day 21 (18.2) 56 (35.2) <0.001 
 - Re-escalation to 400 mg/day 15/21 (71.4) 34/56 (60.7) 0.691 
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TABLE 4. Reasons leading to sorafenib permanent discontinuation 
Reason for discontinuation 2008 - 2012 period (n=154) 2013 - 2017 period (n=180)* P 
 - Progression 98 (63.6) 129 (71.7) 0.127 
 - Intolerance 32 (20.8) 17 (9.4) <0.001 
 - Liver failure 20 (13.0) 26 (14.4) 0.752 
 - Other 4 (2.6) 8 (4.4) 0.557 
 
* Four patients still receiving sorafenib in this group 
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TABLE 5. Predictors of survival according to the multivariable Cox regression performed using appearance 
of dermatological adverse events as a time-dependent variable. 
Univariate analysis 
Variable 
Multivariate analysis 
HR 95% CI P HR 95% CI P 
1.190 0.834-1.699 0.337 Age > 70 years  -   -   -  
1.034 0.815-1.311 0.784 Male gender  -   -   -  
1.011 0.722-1.300 0.733 Viral etiology  -   -   -  
0.888 0.789-1.000 0.049 
Time since first HCC diagnosis > 
12 months  -   -  0.723 
2.638 1.751-3.972 <0.001 Child Pugh B status 2.093 1.364-3.211 0.001 
1.651 1.287-2.118 <0.001 Performance status  (0 vs 1) 1.357 1.043-1.765 0.023 
1.770 1.373-2.282 <0.001 Macrovascular invasion 1.722 1.331-2.622 <0.001 
1.250 0.989-1.584 0.095 Extrahepatic spread  -   -  0.111 
1.486 1.147-1.924 0.003 Alfa-fetoprotein >400 ng/ml 1.328 1.024-1.724 0.033 
0.562 0.436-0.725 <0.001 Dermatological AEs 0.624 0.482-0.808 <0.001 
0.694 0.547-0.880 0.003 
Period of treatment  
(2013-2017 vs 2008-2012) 0.728 0.581-0.937 0.013 
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 FIGURE 1. Radiological response according to the Response Evaluation Criteria in Solid Tumors version 1.1 
at the first imaging follow-up (performed 8-10 weeks after the start of sorafenib) 
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FIGURE 2. Overall survival outcomes 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 24 
 
FIGURE 3. Overall survival (OS) outcomes according to the 12-month (A) and 24-month landmark analyses  1  2 
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FIGURE 4. Overall survival (OS) outcomes stratified according to the first imaging response in progressors 
(A) and responders (B). 
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Graphical Abstract
 Management of sorafenib-related adverse events has changed overtime 
 A tailored approach with more temporary dose reductions is now more frequent 
 Median treatment duration has increased overtime (5.8 vs 4.1 months)  
 More importantly, overall survival has also increased (12.0 vs 11.0 months) 
 Increasing survival  impacts on the design of trials using sorafenib as comparator 
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